title: Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology.
abstract: The everolimus eluting bioresorbable vascular scaffold (BVS) represents a novel technology and a novel paradigm for treatment of coronary artery disease, with the potential of improving the long-term clinical outcomes after complete bioresorption. The increasing amount of clinical data is adding in a gradual understanding of the appropriate implantation technique, but long-term results after BVS implantation are sparse. In addition, concern related to a possible increased rate of scaffold thrombosis has recently risen. The present article reviews the current status of knowledge on bioresorbable vascular scaffold from the preclinical phase and the first-in-man experience to the recently reported large randomized trials. Challenging subsets are discussed as well as possible factors impacting on the occurrence of thrombotic events, particularly focusing on clinical outcomes reported in the longest follow-ups currently available.
authors.affiliation: Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands - r.diletti@erasmusmc.nl.
authors.forename: Wijnand K
authors.initials: WK
authors.lastname: DEN Dekker
authors.forename: Robert J
authors.initials: RJ
authors.lastname: VAN Geuns
authors.forename: Roberto
authors.initials: R
authors.lastname: Diletti
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D003324:Coronary Artery Disease / Q000601:surgery; D054855:Drug-Eluting Stents; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D012449:Safety; D054457:Tissue Scaffolds / Q000009:adverse effects*; D016896:Treatment Outcome